

Resource Summary Report

Generated by [ASWG](#) on Aug 3, 2026

Phoenix

RRID:SCR_003163

Type: Tool

Proper Citation

Phoenix (RRID:SCR_003163)

Resource Information

URL: http://www.stanford.edu/group/nolan/retroviral_systems/phx.html

Proper Citation: Phoenix (RRID:SCR_003163)

Description: A second-generation retrovirus producer lines for the generation of helper free ecotropic and amphotropic retroviruses. The lines are based on the 293T cell line (a human embryonic kidney line transformed with adenovirus E1a and carrying a temperature sensitive T antigen co-selected with neomycin). The unique feature of this cell line is that it is highly transfectable with either calcium phosphate mediated transfection or lipid-based transfection protocols-- up to 50% or higher of cells can be transiently transfected. The lines were created by placing into 293T cells constructs capable of producing gag-pol, and envelope protein for ecotropic and amphotropic viruses. The lines offered advantages over previous stable systems in that virus can be produced in just a few days. Academic and non-profit laboratories may obtain the Phoenix cells from either Allele Biotechnology or the National Gene Vector Bank. The vectors may be obtained from Addgene. They are no longer distributing these reagents from the lab.

Abbreviations: Phoenix

Synonyms: Phoenix helper, Phoenix system

Resource Type: biomaterial supply resource, cell repository, material resource

Keywords: retrovirus, episome, producer line, cell line, vector

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Phoenix

Resource ID: SCR_003163

Alternate IDs: nlx_156864

Record Creation Time: 20220129T080217+0000

Ratings and Alerts

No rating or validation information has been found for Phoenix.

No alerts have been found for Phoenix.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3031 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Schram AM, et al. (2025) The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(23), 4933.

Clarke D, et al. (2025) A vascular-associated fibroblastic cell controls pancreatic islet immunity. Cell reports, 44(9), 116189.

Ku G, et al. (2025) A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(23), 4944.

Motch Perrine SM, et al. (2025) Embryonic cranial cartilage defects in the Fgfr3Y367C +/- mouse model of achondroplasia. Anatomical record (Hoboken, N.J. : 2007), 308(7), 1893.

Schröder A, et al. (2025) During high salt treatment myeloid p38 γ /MAPK fosters osteoclast activity and inflammatory macrophage responses promoting orthodontic tooth movement. Frontiers in immunology, 16, 1571268.

Bowman EA, et al. (2025) Invasive Buffelgrass, Cenchrus ciliaris, Balances Opportunistic Acquisition of Foliar fungi With Host and Environmental Filtering in Its Introduced Range. Molecular ecology, 34(2), e17609.

Yeung SA, et al. (2025) The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration. British journal of clinical pharmacology, 91(4), 1191.

Kantak S, et al. (2025) Preclinical Characterization of XB002, an Anti-Tissue Factor Antibody-Drug Conjugate for the Treatment of Solid Tumors. Molecular cancer therapeutics, 24(2), 251.

Ogbuagu OE, et al. (2025) Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered. *AIDS (London, England)*, 39(6), 639.

Liu H, et al. (2025) Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension. *International journal of nanomedicine*, 20, 871.

Ibrahim AM, et al. (2025) A novel polysaccharide in the envelope of *S. aureus* influences the septal secretion of preproteins with a YSIRK/GXXS motif. *Journal of bacteriology*, 207(2), e0047824.

Mao X, et al. (2025) A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults. *Clinical and translational science*, 18(1), e70095.

Sangana R, et al. (2025) Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with *Plasmodium falciparum* Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study. *Journal of clinical pharmacology*, 65(2), 179.

Shen S, et al. (2025) Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models. *The Journal of clinical investigation*, 135(6).

Kumagai Y, et al. (2025) Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies. *British journal of clinical pharmacology*, 91(8), 2340.

Demiss M, et al. (2025) Teff Yield and Nutrient Uptake Partitioning During Prolonged Waterlogging: A Preliminary Greenhouse Study. *Plant-environment interactions (Hoboken, N.J.)*, 6(2), e70043.

Cui J, et al. (2025) Mitochondrial Genome Insights into Evolution and Gene Regulation in *Phragmites australis*. *International journal of molecular sciences*, 26(2).

Liu TJ, et al. (2025) Evaluation of a fluorophore for marking navel orangeworm (*Lepidoptera: Pyralidae*). *Journal of insect science (Online)*, 25(1).

AnandaKumar SR, et al. (2025) Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats. *Scientific reports*, 15(1), 3141.

Sheng YH, et al. (2025) Pharmacokinetics of Nivolumab and Erythropoietin in a Rat Model of Diet-Induced Obesity. *Pharmaceutical research*, 42(2), 271.